Efficacy and safety of lebrikizumab treatment in adults and adolescents with moderate to severe atopic dermatitis.

CLINICAL TRIAL WITH MEDICINES

Home · Ee11-Immune-mediated Skin Diseases (Emerging)

Clinical trial information

Promoter: ICON CLINICAL RESEARCH LTD
Phase: III
Execution start: 20/05/2024
End of execution: 17/07/2026
PI: RICARDO RUIZ VILLAVERDE